Table 1.
Baseline Characteristics of All Analyzed Episodesa
| Characteristic | Analyzed Episodes (n = 203) (%) |
|---|---|
| Male | 117 (57.6) |
| Age (±SD) | 52.0 (±14.4) |
| Hematologic Diseases | |
| AML | 115 (56.7) |
| MM or amyloidosis | 30 (14.8) |
| Lymphoma | 26 (12.8) |
| MDS | 12 (5.9) |
| ALL | 10 (4.9) |
| Others | 10 (4.9) |
| Indication of the Prophylaxis | |
| Induction chemotherapy for AML or MDS | 89 (43.8) |
| Autologous SCT | 53 (26.1) |
| Allogeneic SCT | 48 (23.6) |
| Treatment for GVHD | 13 (6.4) |
| Other Underlying Diseases | |
| Hypertension | 28 (13.8) |
| DM | 22 (10.8) |
| Solid malignancy | 18 (8.9) |
| Chronic liver disease | 6 (3.0) |
| Chronic kidney disease | 3 (1.5) |
| Antimold Prophylaxis | |
| Agents used | |
| Posaconazole | 101 (49.8) |
| Micafungin | 102 (50.2) |
| Duration of antimold prophylaxis, days, median (IQR) | 20 (17–29) |
| BDG Tests | |
| The number of BDG tests, median (IQR) | 3 (2–4) |
| Duration of the prophylaxis before the first BDG, median (IQR) | 6 (3–11) |
| The interval between BDG tests, days, median (IQR) | 4 (3–7) |
| In-hospital mortality | 20 (9.9) |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; BDG, β-d-glucan; DM, diabetes mellitus; GVHD, graft-versus-host disease; IQR, interquartile range; MDS, myelodysplastic syndrome; MM, multiple myeloma; SCT, stem cell transplantation; SD, standard deviation.
aData are presented as n (%), if not otherwise specified.